Unleashing therapeutic biology

Creating antibody activators for key disease targets

Target Challenge

Key targets lack drugs

Millions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets.

Drug Challenge

Existing drugs lack specificity

Small molecules or peptides often have off-target interactions, resulting in intolerable side effects.

Antibody Challenge

Antibodies are specific 
but lack activity

Antibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.

Targets Challenge

Key targets lack drugs

Millions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets.

Drugs Challenge

Existing drugs lack specifity

Small molecules or peptides often have off-target interactions, resulting in intolerable side effects.

Antibodies Challenge

Antibodies are specific 
but lack activity

Antibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.

Swipe
Arrow right
Proteins over membraneStylized light blue letter "W" with whimsical curls on a black background.AntibodyProteinBlue proteins

We create target-activating antibodies that unlock key challenging disease targets

FAST

We have developed our Functional Antibody Selection Technology (FAST) platform to rapidly create difficult-to-discover antibody activators for challenging and promising target classes. We focus first on key G-protein coupled receptors (GPCRs), which play a role in regulating nearly every biological area.

What makes us different?

We tackle GPCRs, the hardest target class for antibodies

Unlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.

Kidney
Brain
GPCR
Heart
Stomach
100 million

We measure function not just binding: 100M antibodies at once, 100X more than others

We biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.

We have enabled AI to predict activating antibodies, a first in the field

We don’t only discover rare activators. Our large, proprietary activity datasets pave the path to AI-guided antibody design.

Protein and antibodyComputer
Only
Antibody
6 GPCR
have had antibody activators discovered for them.
Row of 3D grey and blue cylindrical shapes representing data or sound waves.
Abalone Bio
has unlocked
Antibody
2 of them

It's not just an idea. We've already done it twice

We’ve built and derisked the platform and are currently creating activating antibodies for our internal pipeline and our partners.

We tackle GPCRs, the hardest target class for antibodies

Unlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.

We measure function not just binding: 100M antibodies at once, 100X more than others

We biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.

We have enabled AI predict active antibodies, a first in the field

We haven’t just discovered rare activators. Using our  large proprietary activity datasets , we have compiled large-scale activity data that paves the path to design.

We have created agonists for our internal programs and pharma partners

Our system works: we have discovered activators for 2 GPCRs - only 4 others have even been done before us.

Discovering the next generation of antibody drugs

Richard Yu, PhD
CEO and Co-Founder
Arrow rightArrow right
Toshi Takeuchi, PhD
CSO
Arrow rightArrow right
Monica Schwartz, PhD
VP of Antibody Discovery
Arrow rightArrow right
Lauren Schwimmer
VP of Preclinical Development
Arrow rightArrow right
Sameer Soi
VP of data science & AI
Arrow rightArrow right
Richard Yu, PhD
CEO and Co-Founder
Arrow right
Toshi Takeuchi, PhD
CSO
Arrow right
Monica Schwartz, PhD
VP of Antibody Discovery
Arrow right
Lauren Schwimmer
VP of Preclinical Development
Arrow right
Sameer Soi
VP of data science & AI
Arrow right
Swipe
Arrow right